P eriprocedural bleeding events are one of the most common complications after percutaneous coronary intervention (PCI), and patients with periprocedural bleeding have increased risks of readmission for treatment of recurrent bleeding, major adverse cardiovascular events, and all-cause mortality, compared with those without. [1] [2] [3] [4] [5] The incidence rate of periprocedural bleeding for PCI has been reduced by following various bleeding avoidance strategies, such as radial approach, vascular closure devices, and bivalirudin, but the incidence is still relatively high in some studies. [6] [7] [8] The incidence rates of major PCI-related periprocedural bleeding in Japanese patients with acute coronary syndrome were reported to be 4.8% for the femoral approach and 1.1% for the radial approach, and those for elective PCI for coronary artery disease (CAD) were reported to be 2.2% for the femoral approach and 0.2% for the radial approach. 9 Previous studies showed that patients' characteristics, clinical presentation, cardiac biomarkers, procedural characteristics, and the choice of antithrombotic therapies were significant periprocedural bleeding risk factors. 3, 10 However, it is still unclear how total antithrombotic effect in which different types of drugs affected might be associated with periprocedural bleeding events in CAD patients undergoing PCI. The Total Thrombus-formation Analysis System (T-TAS â ; Fujimori, Co, Tokyo, Japan), a microchip-based flow chamber system for evaluation of whole-blood thrombogenicity, was recently developed as an easy-to-use system for quantitative analysis of thrombus formation. 11, 12 Using this system, we reported previously the usefulness of the area under the flow pressure curve under constant flow speed of 10 lL/min until 30 minutes for the atheroma (AR) chip (AR 10 -AUC 30 ) levels determined by T-TAS â , in the assessment of the pharmacological effects of edoxaban, a direct oral anticoagulant, in patients who undergo total knee arthroplasty, 13 and that the AR 10 -AUC 30 level was a significant predictor of the efficacy of vitamin K antagonist and other direct oral anticoagulants. 14 We also reported that low AR 10 -AUC 30 level was a significant predictor of periprocedural bleeding events in patients with atrial fibrillation who undergo catheter ablation, 14 and that the area under the flow pressure curve under constant flow speed of 10 lL/min until 30 minutes for the platelet (PL) chip (PL 24 -AUC 10 ) level measured by T-TAS â is a potentially suitable index for the assessment of antiplatelet therapy in CAD patients. 15 The present study was designed to determine the association of periprocedural bleeding events with platelet thrombus formation, which was estimated quantitatively by T-TAS â . Our results highlighted the utility of T-TAS â in predicting periprocedural bleeding in CAD patients undergoing PCI.
Methods Study Population and Protocol
A total of 690 consecutive patients who underwent scheduled coronary angiography at Kumamoto University Hospital between September 2013 and March 2016 were screened in this study. Patients with end-stage renal dysfunction, and those with acute coronary syndrome, defined as acute myocardial infarction (with or without ECG evidence of ST-segment elevation), were not included in this screening. We excluded 365 patients who underwent coronary angiography only whereas the remaining 325 patients who underwent PCI were enrolled in this study. Of the latter group, we excluded patients on antiplatelet therapy other than dual antiplatelet therapy (DAPT) of aspirin and clopidogrel or prasugrel. The remaining 313 patients were the subjects of this study ( Figure 1 ). Blood samples were obtained from the femoral vein by the 6-Fr sheath before treatment with unfractionated heparin at the time of the first coronary angiography or at the time of PCI. We measured PL 24 -AUC 10 and AR 10 -AUC 30 levels using T-TAS â (n=311), and P2Y12 reaction units (PRU; n=274) using VerifyNow (Ultegra rapid platelet function assay; Accumetrics Inc, San Diego, CA) systems. 16, 17 Patients were divided into 2 groups; those with and without periprocedural bleeding events (see below for definition of periprocedural bleeding events). Each group was also divided into 2 subgroups according to the approach site: femoral approach (n=176) and radial approach (n=137). The study protocol was approved by the human ethics committee of Kumamoto University (Kumamoto, Japan) and informed consent was obtained from each patient or the family of the subject.
Details of DAPT
In the present study, all patients under analysis were being treated with aspirin and clopidogrel or prasugrel. All patients had been treated with 100 mg/day of aspirin from before admission. With regard to patients on clopidogrel, they had been treated with 75 mg/day of clopidogrel (representing the maintenance dose) from before admission or treated with 300 mg of clopidogrel as loading dose the night before their first coronary angiography or PCI. For patients on prasugrel, they had been treated with 3.75 mg/day of prasugrel (representing the maintenance dose used in Japan) from before the admission or treated with 20 mg of prasugrel (representing the loading dose in Japan) the night before their first coronary angiography or PCI.
Definition of Bleeding
All periprocedural bleeding events associated with arterial puncture site occurring on admission were recorded. A TR band (Terumo Corporation, Tokyo, Japan) for hemostasis was applied in patients who underwent puncture of the radial artery, whereas manual compression, Angio-Seal (St. Jude Medical, Inc, Saint Paul, MN), or Perclose ProGlide (Abbott Vascular Co, Abbott Park, IL), was used for vascular closure in patients who underwent puncture of the femoral artery. We defined periprocedural bleeding as a composite of the International Society on Thrombosis and Hemostasis major bleeding, 18 access site hematoma required additional manual compression, and hematoma related with arteriovenous shunt or pseudoaneurysm.
Measurement of Thrombogenicity by T-TAS
â Details of the method used for measurement of platelet thrombus formation by T-TAS â were reported previously.
11,19
To monitor platelet thrombus formation, blood samples were collected into hirudine-anticoagulant tubes, then placed in a reservoir connected to a precision pump. In this study, we measured platelet thrombus formation at flow rate of 24 lL À1 , corresponding to initial shear rates of 2000 s À1 .
When reaction began, blood flew through the collagencoated analytical path of the microchip. The analytical path held 25 capillary channels 40 lm wide940 lm deep coated with type I collagen, and the small platelet aggregates gradually increased in size resulting in increased flow pressure. Flow pressure in the analytical path was measured continuously. We also measured the area under the curve (less than 60 kPa) of flow pressure for 10 minutes after the start of the assay. We described the area under the curve as PL 24 -AUC 10 , corresponding to a flow rate of 24 lL/min for the PL chip. For monitoring white thrombus formation, blood samples were collected into plastic tubes containing 3.2% sodium citrate. Citrated whole blood (480 lL) was mixed with 20 lL of 0.3 mol/L CaCl 2 and set into the reservoir. Blood was pushed into the analytical path, which contained a single capillary channel 300 lm wide980 lm deep coated with type I collagen plus tissue thromboplastin. White thrombus formation was monitored by flow pressure changes. The measurement was performed under a constant flow rate of 10 lL/min, corresponding to 600 s À1 for the AR chip (described as AR 10 -AUC 30 ).
Measurement of Residual Platelet Aggregation
PRU was measured using the VerifyNow system. Blood samples for the P2Y12 cartridge were withdrawn into 1.8-mL blood collection tubes containing 3.2% sodium citrate. In this assay, fibrinogen-coated microparticles were used in the VerifyNow P2Y12 cartridge to bind to available platelet receptors. The results were reported in PRU, which represented the amount of adenosine diphosphate-mediated aggregation specific to the platelet P2Y12 receptor. PRU was determined based on the rate and extent of platelet reactivity in the adenosine diphosphate channel.
Statistical Analysis
Data are expressed as meanAESD. PL 24 
Results

Patient Characteristics and Frequency of Periprocedural Bleeding Events
Of the 325 study patients, we excluded 12 patients who received DAPT other than aspirin and clopidogrel or prasugrel. Five patients were treated with aspirin only. Six were under DAPT other than aspirin and clopidogrel or prasugrel. One Patients with periprocedural bleeding events were significantly older, not diabetic with peripheral arterial disease (PAD), and had lower BMI, platelet count and activated partial thromboplastin time, compared with those without. Furthermore, patients with periprocedural bleeding events were more often treated with prasugrel and had more complex culprit lesions classified into type B2 or type C lesion according to the American College of Cardiology/American Heart Association definition 20 than those without.
Among the 313 patients, 176 underwent PCI through the femoral artery. Of these, 150 (85.2%) did not suffer periprocedural bleeding events whereas 26 (14.8%) did. On the other hand, PCI was performed through the radial artery in 137 patients, and 11 (8.0%) developed periprocedural bleeding events, whereas 126 (92.0%) did not. In this study, 84 patients underwent PCIs through both the femoral and radial approaches; but these patients were included in the femoral group and did not develop periprocedural bleeding events associated with the radial approach.
Twelve (3.8%) patients developed major bleeding complications, defined as International Society on Thrombosis and Hemostasis major bleeding, and all underwent PCI through the femoral artery. They included 5 with retroperitoneal bleeding, 5 with major hematoma requiring ≥2 units of transfusion, 1 with pericardial effusion, and 1 required ≥2 units of transfusion attributed to bleeding from undetermined location. Other minor bleeding events occurred in 25 patients (8.0%), including minor hematoma requiring additional manual compression (n=17), minor bleeding requiring additional manual compression (n=5), arteriovenous shunt (n=1), and pseudoaneurysm (n=2). None of the patients suffered ≥2 bleeding events. Patient Characteristics According to Approach Site Table 2 lists the clinical characteristics of patients of the femoral and radial approach groups. In the femoral approach group, patients with periprocedural bleeding events were significantly older, and had lower BMI and activated partial thromboplastin time, than those without. In the radial approach group, patients with periprocedural bleeding events were significantly older, had lower BMI, PAD, hemoglobin level, and platelet count, and had higher ejection fraction than those without. Furthermore, patients with periprocedural bleeding events were treated with smaller amount of unfractionated heparin than those without. For the femoral approach group (Table 2 and Figure 4 ), PL 24 For the radial approach group (Table 2 and Figure 5 ), PL 24 -AUC 10 , AR 10 -AUC 30 , and PRU levels were identical in patients with and without periprocedural bleeding events (PL 24 
T-TAS â Parameters and PRU Levels in Each Group
Predictors of Periprocedural Bleeding Events
Finally, we used logistic regression analyses to determine the factors that can predict periprocedural bleeding events. The result of simple regression analysis of the entire patients group is shown in Table 3 . Simple logistic regression analysis demonstrated that old age, low BMI, PAD, diabetes mellitus, platelet counts, activated partial thromboplastin time, complex culprit legion, and low PL 24 -AUC 10 level correlated with periprocedural bleeding events. Multiple logistic regression analyses identified low PL 24 -AUC 10 level as a significant predictor of periprocedural bleeding events in 3 forced inclusion models (Table 4) , with a Hosmer-Lemeshow goodness-of-fit chi-square of 6.802 (P=0.236) in model 1, 5.068 (P=0.750) in model 2, and 9.840 (P=0.276) in model 3.
The results of simple regression analyses of subgroups are shown in Table 5 . In the femoral approach group, simple logistic regression analysis demonstrated that activated partial thromboplastin time and low PL 24 -AUC 10 level correlated with periprocedural bleeding events. In the radial approach group, simple logistic regression analysis demonstrated that old age, low BMI, and PAD were correlated with periprocedural bleeding events. Multiple logistic regression analyses using 3 forced inclusion models identified that only low PL 24 -AUC 10 level was the significant predictor of periprocedural bleeding events of the femoral approach group in all 3 models (Table 6) , with a Hosmer-Lemeshow goodness-of-fit chi-square of 1.806 (P=0.614) in model 1, 0.907 (P=0.924) in model 2, and 4.165 (P=0.842) in model 3. We did not perform multiple logistic regression analysis in the radial group because of the small number of periprocedural bleeding events.
Discussion
In the present study, we investigated the association between T-TAS â parameters and periprocedural bleeding events in CAD patients who underwent PCI. The main finding of this study is that low PL 24 -AUC 10 level is a significant predictor of periprocedural bleeding events in CAD patients who undergo PCI by the femoral approach. To our best knowledge, this is the first report that describes the usefulness of T-TAS â for prediction of periprocedural bleeding events in CAD patients undergoing PCI. Although the concept of this study was similar to our previous report, 14 the study subjects (atrial fibrillation versus CAD), blood flow conditions of the puncture site (vein versus artery), and type of antithrombotic therapy (anticoagulants versus antiplatelets) are different between 2 studies.
Several factors, including low BMI, old age, presence of PAD and diabetes mellitus, female sex, renal dysfunction, and procedural characteristics, have been identified as predictors of periprocedural bleeding events.
3,5,10,21-23 Furthermore, several studies described the association between platelet reactivity and bleeding events. 24, 25 In subanalysis of the ADAPT-DES (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents) study, the lowest PRU quintile (PRU<95) was associated with significantly higher risk of clinically relevant bleeding compared with the other 4 groups. 24 Kim et al 25 tested the diagnostic utility of 3 conventional plateletactivity assays (light transmittance aggregometry, VerifyNow, and multiple electrode aggregometry) to define the predictive value of low platelet reactivity for bleeding within 1 year after stenting. They reported that only parameters measured by VerifyNow were independent predictors for bleeding events. However, to our knowledge, there are no studies that examined the association between total antithrombotic effects of various antithrombotic agents and periprocedural bleeding events because of the difficulty in measuring total thrombogenicity affected by different pharmacological effects. In this study, we found that low levels of PL 24 -AUC 10 at the time of PCI were associated with periprocedural bleeding events in CAD patients. Further studies are needed to confirm the finding that PL 24 -AUC 10 measured by T-TAS â is a potentially useful predictor of periprocedural bleeding events post-PCI in patients with CAD.
In our study, the predictors of periprocedural bleeding events were different between the femoral and radial approach groups. In the femoral approach group, low PL 24 -AUC 10 levels correlated with periprocedural bleeding events in CAD patients who underwent PCI, whereas in the radial approach group, low PL 24 -AUC 10 levels did not correlate with periprocedural bleeding events. In the present study, we used a single standard device for compression in the radial approach group, whereas manual compression or vascular closure devices were used in the femoral approach group. Based on the small number of bleeding events, and no major bleeding events in the radial approach, it is possible that statistical power was not strong enough to select PL 24 -AUC 10 level as a significant predictor of periprocedural bleeding events in the radial approach group. Furthermore, based on the same reasons, it is difficult to conclude that the radial approach is superior to the femoral approach with regard to periprocedural bleeding events.
Our study has several limitations. First, this study was performed in a single center with a relatively small study population. Further multiple center studies that include large numbers of subjects are needed to determine the true association between PL 24 -AUC 10 levels and major periprocedural bleeding events. Second, the study included only a small group of patients who were treated with both antiplatelet and anticoagulant therapies. Further studies are needed to evaluate the association between periprocedural bleeding events and high-risk patients treated with both antiplatelet agents and anticoagulants. Third, we did not evaluate the association between T-TAS â parameters and long-term prognosis in the present study. We need to examine whether PL 24 -AUC 10 levels measured by T-TAS â correlate with longterm bleeding or ischemic events in CAD patients. Periprocedural bleeding events are associated with adverse clinical events post-PCI in patients with CAD undergoing PCI. We might be able to reduce periprocedural bleeding events by detecting patients with high risk of periprocedural bleeding events by using T-TAS â . Previous studies [26] [27] [28] reported no improvement in the clinical outcome of patients post-PCI by adjusting antiplatelet therapies using VerifyNow. If evidences for the association between parameters of T-TAS â and clinical events in CAD patients are accumulated, monitoring thrombogenicity to adjust antiplatelet therapy for each patient by using T-TAS â would improve the clinical outcome of patients with CAD undergoing PCI.
Conclusions
The results of the present study demonstrated that low PL 24 -AUC 10 level measured by T-TAS â was a significant predictor of periprocedural bleeding events in CAD patients post-PCI, especially in patients who undergo PCI through the femoral approach. T-TAS â is potentially useful for the prediction of periprocedural bleeding events in CAD patients undergoing PCI.
